Prosecution Insights
Last updated: May 29, 2026
Application No. 18/706,245

HYDRATABLE CONCENTRATED SURFACTANT COMPOSITIONS

Non-Final OA §103§112§DOUBLEPATENT
Filed
Apr 30, 2024
Priority
Nov 29, 2021 — EU 21211171.0 +1 more
Examiner
GOTFREDSON, GAREN
Art Unit
1619
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
CONOPCO, INC.
OA Round
1 (Non-Final)
40%
Grant Probability
Moderate
1-2
OA Rounds
1y 9m
Est. Remaining
69%
With Interview

Examiner Intelligence

Grants 40% of resolved cases
40%
Career Allowance Rate
215 granted / 537 resolved
-20.0% vs TC avg
Strong +29% interview lift
Without
With
+29.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
46 currently pending
Career history
597
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
53.5%
+13.5% vs TC avg
§102
21.9%
-18.1% vs TC avg
§112
2.5%
-37.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 537 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
DETAILED ACTION Claims 1-16 are pending. Of these, claims 7-13 are withdrawn as directed to a nonelected invention. Therefore, claims 1-6 and 14-15 are under consideration on the merits. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Election/Restriction Applicant’s election of Group I, claims 1-6 and 14-15, is acknowledged. The election having been made without traverse, the restriction requirement is still considered proper and is therefore made FINAL. Information Disclosure Statement The information disclosure statement (IDS) submitted on 9/17/23, 8/7/25, 3/4/26, and 4/3/26 was filed prior to the mailing date of a first Action on the merits. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, it was considered by the Examiner. Claim Objections Claims 2-3 are objected to because of the following informalities: Claims 2-3 recites improper Markush language. The claims should recite “selected from the group consisting of.” Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-6 and 14-15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites that “the surfactants are in a lamellar phase,” which is unclear, because claim 1 recites both an anionic surfactant and a co-surfactant. Is the co-surfactant considered a “surfactant” for the purpose of this limitation? Clarification is required. Since dependent claims 2-6 and 14-15 do not clarify the point of confusion, they are also rejected. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1- 6 and 14-15 are rejected under 35 U.S.C. 103 as unpatentable over Mould et al. (WO 94/16680; of record in IDS) in view of Dixon et al. (GB2297762). As to claims 1-6 and 14-15, Mould discloses a hydratable concentrated surfactant personal washing composition comprising 36 wt% sodium laureth ether sulphate (SLES) anionic surfactant, 9 wt% cocamidopropyl betaine (CAPB) cosurfactant (claim 2), 2 wt% sodium chloride (“a “viscosity modifier” that is an “inorganic electrolyte” of claim 1 and a “metal chloride” of claim 3), and 49.1 wt% water to balance, the foregoing amounts being within the ranges recited by claim 1 and which results in a weight ratio of anionic surfactant to cosurfactant of 36:9 or 4:1, which is within the ranges of claims 1 and 4. The composition further may comprise a preservative such as sodium benzoate in the amount of 0.5-5 wt% (page 9, first two paragraphs), which reads on the ratios of sodium benzoate to total surfactant recited by claims 1 and 14-15. For example, the use of 3 wt% sodium benzoate, 36% sodium laureth sulphate, and 9 wt% cocamidopropyl betaine results in a ratio of 3:45 or 1:15. The composition is in a lamellar phase (page 3, lines 12-13). Regarding claim 6, although Mould teaches that the composition may comprise a a conditioning agent and that one example of a suitable conditioning agent is a silicone, Mould does not require the use of a silicone, thereby meeting the negative limitation of the claim (page 7, 1st full paragraph and page 8, 2nd full paragraph). As to claims 1-6 and 14-15, Mould does not further expressly disclose that the composition has a pH of 3-6 as recited by claim 1 nor a viscosity within the 5000-100,000 cps range of claim 1, nor that the composition comprises ethylenediaminetetraacetic acid (claim 5). Dixon discloses personal cleansing compositions such as shampoos comprising surfactants (Abstract) such as betaines or sodium laureth sulfates (page 10) and additional ingredients such as sodium benzoate as a preservative (page 18, 1st full paragraph) and ethylene diaminetetraacetic acid as a calcium and magnesium ion sequestrant to provide lather boosting properties under hard water usage conditions (paragraph bridging pages 17-18). The composition may be lamellar (page 9, 1st paragraph). The pH of the composition is adjusted to about 4-8 using a buffer system (page 18, 2nd full paragraph). The compositions have a viscosity of 10,000-40,000 cps (page 2, last paragraph), As to claims 1-6 and 14-15, it would have been prima facie obvious to one of ordinary skill in the art at the effective filing date of the present invention to modify the personal washing composition of Mould by selecting a viscosity and pH within the range of claim 1, because Dixon teaches that personal cleansing compositions comprising betaines, sodium laureth sulfates, and/or sodium benzoate suitably may have a viscosity and pH within the claimed range such that the skilled artisan reasonably would have expected that such viscosities and pH values would be appropriate for the Mould personal cleansing composition. Discovering optimum or working ranges involves only routine skill in the art in cases where the general conditions of a claim are disclosed in the prior art. In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Regarding claim 5, it further would have been prima facie obvious to incorporate ethylenediaminetetraacetic acid because Dixon teaches that doing so will advantageously boost lathering properties under hard water usage conditions. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 1- 6 and 14-15 are provisionally rejected on the ground of nonstatutory double patenting as unpatentable over all claims of US Pat. Appl. No. 18/706,663. The teachings of Mould are relied upon as discussed above. Although the reference claims are not identical, they are not patentably distinct because the reference claims recite a hydratable concentrated surfactant composition comprising 30-50 wt% sodium laureth ether sulfate, 4-12% betaine cosurfactant or cocamide monoethanolamide, 0.2-3% sodium benzoate, 0.2- 3% inorganic electrolyte such as a metal chloride, and 10-60% water, wherein the composition is in a lamellar phase and the pH is 3-6 and the composition has a viscosity of 8000-200,000 cps, the composition further comprising ethylenediaminetetraacetic acid and is free from silicone, the ratio of the sodium benzoate to total surfactant and of the anionic surfactant to cosurfactant being within the claimed ratios. Claims 1- 6 and 14-15 are provisionally rejected on the ground of nonstatutory double patenting as unpatentable over all claims of US Pat. Appl. No. 18/711,038. Although the reference claims are not identical, they are not patentably distinct because the reference claims recite a hydratable concentrated surfactant composition comprising 30-50 wt% sodium laureth ether sulfate, 4-12% betaine cosurfactant or cocamide monoethanolamide, 0.2-3% sodium benzoate, 0.2- 3% inorganic electrolyte such as a metal chloride, and 10-60% water, wherein the composition is in a lamellar phase and the pH is 3-6 and the composition has a viscosity of 8000-200,000 cps, the composition further comprising ethylenediaminetetraacetic acid and is free from silicone, the ratio of the sodium benzoate to total surfactant and of the anionic surfactant to cosurfactant being within the claimed ratios. Although the reference claims are not identical, they are not patentably distinct because the reference claims recite a hydratable concentrated surfactant composition comprising 30-50 wt% sodium laureth ether sulfate, 4-12% betaine cosurfactant or cocamide monoethanolamide, 0.2-3% sodium benzoate, 0.2- 3% inorganic electrolyte such as a metal chloride, and 10-60% water, wherein the composition is in a lamellar phase and the pH is 3-6 and the composition has a viscosity of 8000-200,000 cps, the composition further comprising ethylenediaminetetraacetic acid and being substantially free from silicone, the ratio of the sodium benzoate to total surfactant and of the anionic surfactant to cosurfactant being within the claimed ratios. Claims 1- 6 and 14-15 are provisionally rejected on the ground of nonstatutory double patenting as unpatentable over all claims of US Pat. Appl. No. 18/578,443 and in view of Mould et al. (WO 94/16680) and/or Dixon et al. (GB2297762) where indicated below. The teachings of Mould and Dixon are relied upon as discussed above. Although the reference claims are not identical, they are not patentably distinct because the reference claims recite a hydratable concentrated surfactant composition comprising 5-40 wt% sulfate-free anionic surfactant, 5-12% of an amphotheric such as a betaine, 0.1- 5% inorganic electrolyte, a preservative, and 10-70 wt% water, wherein the composition is in a lamellar phase and the pH is 3-6 and the composition has a viscosity of 6000-400,000 cps, with a weigtht ratio of anionic to amphoteric surfactant of 1:1 to 1:2. The reference composition does not recite the presence of a silicone. Although the reference claims do not recite that the electrolyte is a metal chloride or that the surfactant comprises sodium laureth ether sulfate or that the betaine is cocamidopropylbetaine or that the preservative is sodium benzoate nor the weight ratios of sodium benzoate to total surfactant and that the composition further comprises ethylenediaminetetraacetic acid, it would have been prima facie obvious to make these modifications since Mould teaches that for a similar hydratable concentrated surfactant composition comprising anionic surfactant, inorganic electrolyte, and betaine surfactant and a preservative, the preservative may be sodium benzoate, the electrolyte may be a metal chloride, the betaine surfactant may be cocamidopropylbetaine, and the anionic surfactant may be sodium laureth ether sulfate, and the presently claimed weight ratios may be within the claimed ranges, and Dixon teaches that ethylene diaminetetraacetic acid is useful in surfactant compositions as a calcium and magnesium ion sequestrant to provide lather boosting properties under hard water usage conditions, such that the skilled artisan reasonably would have been motivated to make these modifications to the reference claims with a reasonable expectation of success. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to GAREN GOTFREDSON whose telephone number is (571)270-3468. The examiner can normally be reached on M-F 9AM-6PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Blanchard can be reached on 5712720827. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GAREN GOTFREDSON/Examiner, Art Unit 1619
Read full office action

Prosecution Timeline

Apr 30, 2024
Application Filed
Apr 23, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12636256
STARCH FILM-FORMING COMPOSITIONS AND METHODS OF THEIR USE FOR PREPARING CAPSULE SHELLS
3y 10m to grant Granted May 26, 2026
Patent 12622998
LIQUID DRESSING
4y 2m to grant Granted May 12, 2026
Patent 12605321
Personal Care Compositions
5y 0m to grant Granted Apr 21, 2026
Patent 12589061
METHOD FOR PRODUCING SILICA PARTICLES AND THEIR USE IN COSMETIC COMPOSITIONS
4y 11m to grant Granted Mar 31, 2026
Patent 12589077
METHOD FOR PREPARING BIODEGRADABLE MICROCAPSULES AND MICROCAPSULES THUS OBTAINED
2y 11m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
40%
Grant Probability
69%
With Interview (+29.1%)
3y 10m (~1y 9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 537 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month